Cybin Inc. (HELP:NASDAQ) closed at $10.19 on October 23, 2026, down 2.95% on the day. The stock trades 32.7% below its 52-week high of $15.15 and 171.0% above its 52-week low of $3.76. Over the past year, it gained 65.2%. Cybin Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, HELP closed higher on 122 days (48%). Its best day was June 25, 2026 (+18.27%) and its worst was March 5, 2026 (-33.88%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 3 times.
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Find more stocks like HELP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.